Factors affecting the duration of phase I of dexamethasone - cyclophosphamide pulse therapy.
Loading...
Date
2014-07
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: The introduction of dexamethasone-cyclophosphamide pulse (DCP) therapy for
the pemphigus group of disorders by Pasricha has revolutionized the therapy for pemphigus.
There are very few studies regarding factors affecting duration of phase I of the DCP.
Aims: Our purpose was to study the relationship between various factors and duration of the
phase I. Methods: A retrospective study of 98 patients of pemphigus on Dexamethasone
Pulse therapy was conducted. Patients were classified according to duration of Phase 1 as
those with phase I less than 6 months and those more than 6 months and analyzed for variable
factors affecting duration of phase I. Results: Disease severity in pemphigus significantly
prolonged the duration of phase I of DCP. Longer duration was also observed in patients on
concurrent oral steroid therapy (both statistically significant). Conclusion: The findings from
our study help us to address patient expectations and apprehensions regarding duration of
therapy. A detailed understanding of the various patient and disease related factors responsible
for affecting Phase I duration will help in better management of the patient, and the disease.
Description
Keywords
Dexamethasone cyclophosphamide pulse therapy, pemphigus, phase I, pulse therapy
Citation
Nayak Chitra S, Ray Somshukla, Thombre Anil, Jain Mahim. Factors affecting the duration of phase I of dexamethasone - cyclophosphamide pulse therapy. Indian Journal of Dermatology, Venereology and Leprology. 2014 Jul-Aug; 80(4): 296-299.